In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 3.2 below Zynerba Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Quick Ratio than Zynerba Pharmaceuticals Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 701 to 1084.

Explain Quick Ratio?
How much Cash & cash equivalents ZYNE�s has?
What are ZYNE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ZYNE/financial-strength

https://api.csimarket.com/api/v1/companies/ZYNE/fundamentals

https://api.csimarket.com/api/v1/companies/ZYNE/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ZYNE Quick Ratio	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3	(Jun 30 2022) Q2
Y / Y Current Liabilities Change	17.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-42.44 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.2	Subscribe	Subscribe	Subscribe	Subscribe
ZYNE's Total Ranking	# 1084	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	16.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-18.99 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 321
Healthcare Sector	# 544
Overall Market	# 1084

Quick Ratio Statistics
High	Average	Low
16.51	7.16	1.39
(Sep 30 2015)		(Jun 30 2015)

Financial Statements
Zynerba Pharmaceuticals Inc 's Current Liabilities	$ 11 Millions	Visit ZYNE's Balance sheet
Zynerba Pharmaceuticals Inc 's Cash & cash equivalent	$ 36 Millions	Visit ZYNE's Balance sheet
Source of ZYNE's Sales		Visit ZYNE's Sales by Geography

Cumulative Zynerba Pharmaceuticals Inc 's Quick Ratio

ZYNE's Quick Ratio for the trailling 12 Months

ZYNE Quick Ratio	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	0.52 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-32.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.74	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3760	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	4.53 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-12.42 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ZYNE Financial Strength Comparisons >> Go to Compare ZYNE Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2023 to $11.24 millions, cumulative Quick Ratio decreased to 4.74 below the Zynerba Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 531 other companies have achieved higher Quick Ratio than Zynerba Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 590 to 3760.

Explain Quick Ratio?
How much Cash & cash equivalents ZYNE�s has?
What are ZYNE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 532
Healthcare Sector	# 1050
Within the Market	# 3760

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.01	6.77	4.71
(Dec 31 2017)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2023 MRQ Cash & cash equivalent	Jun 30 2023 MRQ Current Liabilities
Igm Biosciences Inc	8.73	$ 386.869 Millions	$ 44.299 Millions
Pepgen Inc	8.68	$ 147.027 Millions	$ 16.936 Millions
Briacell Therapeutics Corp	8.64	$ 21.251 Millions	$ 2.459 Millions
Clene Inc	8.59	$ 49.243 Millions	$ 5.735 Millions
An2 Therapeutics Inc	8.53	$ 95.258 Millions	$ 11.161 Millions
Uniqure N v	8.48	$ 513.598 Millions	$ 60.576 Millions
Immunome Inc	8.34	$ 38.416 Millions	$ 4.606 Millions
Oncolytics Biotech Inc	8.24	$ 26.743 Millions	$ 3.246 Millions
United Therapeutics Corporation	8.12	$ 2,679.000 Millions	$ 329.800 Millions
Crinetics Pharmaceuticals Inc	8.11	$ 264.529 Millions	$ 32.610 Millions
Nektar Therapeutics	8.08	$ 409.432 Millions	$ 50.694 Millions
Cypherpunk Technologies Inc	8.07	$ 91.415 Millions	$ 11.326 Millions
Lumos Pharma Inc	7.99	$ 50.851 Millions	$ 6.366 Millions
Longboard Pharmaceuticals Inc	7.98	$ 63.047 Millions	$ 7.901 Millions
Pulmatrix Inc	7.96	$ 25.791 Millions	$ 3.239 Millions
Lixte Biotechnology Holdings Inc	7.95	$ 2.913 Millions	$ 0.367 Millions
Pds Biotechnology Corp	7.67	$ 60.625 Millions	$ 7.904 Millions
Compass Pathways Plc	7.62	$ 148.485 Millions	$ 19.489 Millions
Vera Therapeutics Inc	7.46	$ 181.021 Millions	$ 24.275 Millions
Ligand Pharmaceuticals Incorporated	7.45	$ 219.041 Millions	$ 29.388 Millions
Capricor Therapeutics inc	7.36	$ 37.793 Millions	$ 5.134 Millions
Arcutis Biotherapeutics Inc	7.33	$ 268.671 Millions	$ 36.659 Millions
Prf Technologies Ltd	7.32	$ 6.162 Millions	$ 0.842 Millions
Marinus Pharmaceuticals Inc	7.29	$ 175.336 Millions	$ 24.047 Millions
Metavia Inc	7.20	$ 28.688 Millions	$ 3.983 Millions
Bolt Biotherapeutics Inc	7.14	$ 125.866 Millions	$ 17.618 Millions
Clearside Biomedical Inc	7.12	$ 35.005 Millions	$ 4.915 Millions
Cormedix Inc	7.09	$ 52.401 Millions	$ 7.387 Millions
Puretech Health Plc	7.05	$ 362.261 Millions	$ 51.370 Millions
Opus Genetics Inc	6.94	$ 39.999 Millions	$ 5.761 Millions

Date modified: 2026-10-07T00:41:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.